{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = [(8''R'',9''S'',10''R'',13''S'',14''S'',17''S'')-13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1''H''-cyclopenta[''a'']phenanthren-17-yl] 3-phenylpropanoate
| image = Nandrolone phenylpropionate.svg
| width = 250px
| image2 = Nandrolone phenylpropionate molecule ball.png
| width2 = 250px

<!--Clinical data-->
| tradename = Durabolin, others
| pregnancy_AU = D
| pregnancy_US = X
| pregnancy_category = 
| legal_AU = S4
| legal_CA = Schedule IV
| legal_UK = Class C
| legal_US = Schedule III
| legal_status = 
| routes_of_administration = [[Intramuscular_injection|Intramuscular injection]]
| class = [[Androgen|Androgen]]; [[Anabolic_steroid|Anabolic steroid]]; [[Androgen_ester|Androgen ester]]; [[Progestogen|Progestogen]]

<!--Pharmacokinetic data-->
| bioavailability = • [[Oral_administration|Oral]]: 0.3–2.9% (pigs)<ref name="pmid10435281">{{cite journal | vauthors = McEvoy JD, McVeigh CE, McCaughey WJ | title = Residues of nortestosterone esters at injection sites. Part 1. Oral bioavailability | journal = Analyst | volume = 123 | issue = 12 | pages = 2475–8 | year = 1998 | pmid = 10435281 | doi = 10.1039/a804919j| url = }}</ref><br />• [[Intramuscular_injection|Intramuscular]]: high<ref name="Becker2001">{{cite book|author=Kenneth L. Becker|title=Principles and Practice of Endocrinology and Metabolism|url=https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1185|year=2001|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-1750-2|pages=1185–}}</ref>
| protein_bound = 
| metabolism = [[Blood|Blood]] ([[hydrolysis|hydrolysis]]), [[liver|liver]] ([[redox|reduction]])<ref name="Label-NZ" /><ref name="Thomas2012">{{cite book|author=John A. Thomas|title=Drugs, Athletes, and Physical Performance|url=https://books.google.com/books?id=9u0pBgAAQBAJ&pg=PA27|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-1-4684-5499-4|pages=27–29}}</ref>
| metabolites = • [[Nandrolone|Nandrolone]]<ref name="Llewellyn2011" /><br />• [[5α-Dihydronandrolone|5α-Dihydronandrolone]]<ref name="Llewellyn2011" /><br />• [[19-Norandrosterone|19-Norandrosterone]]<ref name="Rogozkin1991">{{cite book|author=Victor A. Rogozkin|title=Metabolism of Anabolic-Androgenic Steroids|url=https://books.google.com/books?id=hRsnmJRF1WgC&pg=PA108|date=14 June 1991|publisher=CRC Press|isbn=978-0-8493-6415-0|pages=108–}}</ref><br />• [[19-Noretiocholanolone|19-Noretiocholanolone]]<ref name="Rogozkin1991" /><br />• [[Conjugation_(biochemistry)|Conjugate]]s<ref name="Thomas2012" />
| elimination_half-life = • Intramuscular: 2.7 days<ref name="pmid9103484">{{cite journal | vauthors = Minto CF, Howe C, Wishart S, Conway AJ, Handelsman DJ | title = Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: effects of ester, injection site and injection volume | journal = J. Pharmacol. Exp. Ther. | volume = 281 | issue = 1 | pages = 93–102 | year = 1997 | pmid = 9103484 | doi = | url = }}</ref><br />• Nandrolone: <4.3 hours<ref name="Label-NZ">http://www.medsafe.govt.nz/profs/Datasheet/d/Decadurabolininj.pdf</ref>
| duration_of_action = • Intramuscular: 5–7 days<ref name="Llewellyn2011" /><ref name="pmid9103484" />
| excretion = [[Urine|Urine]]<ref name="Label-NZ" />

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 434-22-0
| CAS_supplemental = 
| ATC_prefix = 
| ATC_suffix = 
| PubChem = 229455
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 199761
| UNII = KF7Z9K2T3W
| synonyms = • NPP<br />• Nandrolone phenpropionate<br />• 19-Nortestosterone phenylpropionate<br />• Nandrolone hydrocinnamate<br />• 19-Nortestosterone 17β-phenylpropionate<br />• NSC-23162

<!--Chemical data-->
| C=27 | H=34 | O=3
| SMILES = C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CCC4=CC=CC=C4)CCC5=CC(=O)CC[C@H]35
| StdInChI_Ref = 
| StdInChI = 1S/C27H34O3/c1-27-16-15-22-21-11-9-20(28)17-19(21)8-10-23(22)24(27)12-13-25(27)30-26(29)14-7-18-5-3-2-4-6-18/h2-6,17,21-25H,7-16H2,1H3/t21-,22+,23+,24-,25-,27-/m0/s1
| StdInChIKey_Ref = 
| StdInChIKey = UBWXUGDQUBIEIZ-QNTYDACNSA-N
}}
{{medical}}
'''苯丙酸诺龙'''（{{lang-en|Nandrolone phenylpropionate}}或 Nandrolone hydrocinnamic，缩写NPP，[[商品名|商品名]]为Durabolin）是一种[[雄激素|雄激素]][[同化類固醇|同化類固醇]]（AAS）[[药物|药物]]，主要用于治疗[[乳腺癌|乳腺癌]]和[[骨質疏鬆症|骨質疏鬆症]]女性<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA660|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=660–}}</ref><ref name="IndexNominum2000">{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA716|date=January 2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=716–717}}</ref><ref name="MortonHall2012">{{cite book|author1=I.K. Morton|author2=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA189|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-4439-1}}</ref><ref name="Drugs.com">https://www.drugs.com/international/nandrolone.html</ref><ref name="Llewellyn2011">{{cite book|author=William Llewellyn|title=Anabolics|url=https://books.google.com/books?id=afKLA-6wW0oC&pg=PT460|year=2011|publisher=Molecular Nutrition Llc|isbn=978-0-9828280-1-4|pages=460–467,193–194}}</ref>，通过每周一次的[[肌肉注射|肌肉注射]]进行<ref name="Llewellyn2011" />。这类药物过去曾广泛应用，但现已逐渐停用<ref name="Llewellyn2011" /><ref name="Drugs.com" />。
[[File:Nandrolone.svg|thumb]]（Nandrolone，'''诺龙'''），NPP的最终[[活性代謝產物|活性形式]]]]
==参考文献==
<references />
{{雄激素}}

[[Category:前药|Category:前药]]
[[Category:药物|Category:药物]]
[[Category:注射药物|Category:注射药物]]